Rockefeller Capital Management’s Pacific Biosciences PACB Stock Holding History

Rockefeller Capital Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.86K	Buy	5,198 +3,952	+317%	+$7.07K	﹤0.01%	4141
2025 Q4	$2.33K	Buy	1,246 +989	+385%	+$1.9K	﹤0.01%	4280
2025 Q3	$329	Buy	+257	New	+$348	﹤0.01%	4318
2023 Q1	–	Sell	-1,018	Closed	-$8K	–	3311
2022 Q4	$8K	Buy	1,018 +527	+107%	+$4.54K	﹤0.01%	3188
2022 Q3	$2K	Sell	491 -826	-63%	-$4.74K	﹤0.01%	3614
2022 Q2	$4K	Sell	1,317 -75,579	-98%	-$459K	﹤0.01%	3561
2022 Q1	$699K	Buy	76,896 +76,582	+24,389%	+$882K	﹤0.01%	1191
2021 Q4	$5K	Buy	+314	New	+$7.58K	﹤0.01%	3282
2021 Q3	–	Sell	-4,413	Closed	-$153K	–	3802
2021 Q2	$153K	Sell	4,413 -461	-9%	-$13.4K	﹤0.01%	1625
2021 Q1	$161K	Sell	4,874 -1,456	-23%	-$51K	﹤0.01%	1395
2020 Q4	$164K	Buy	+6,330	New	+$108K	﹤0.01%	1259

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Rockefeller Capital Management's PACB Position: Q1 2026 in Review

Rockefeller Capital Management increased its Pacific Biosciences (PACB) stake by 317% in Q1 2026, buying an estimated $7.07K and bringing the position to 5,198 shares worth $6.86K. The position accounts for ﹤0.01% of the portfolio, ranked #4141.

Rockefeller Capital Management first reported a position in PACB in Q4 2020 and has held it in 11 quarters since. The position peaked at $699K in Q1 2022. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

Rockefeller Capital Management held 5,198 shares of Pacific Biosciences worth $6.86K as of Q1 2026.
Rockefeller Capital Management bought 3,952 Pacific Biosciences shares in Q1 2026, an estimated $7.07K.
Pacific Biosciences made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #4141 holding.
Rockefeller Capital Management first reported a position in Pacific Biosciences in Q4 2020 and has held it in 11 quarters since.
Rockefeller Capital Management's Pacific Biosciences position peaked at $699K in Q1 2022.
229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.